Avacta has announced its appointment of BBI Solutions, part of BBI Group (‘BBI’), to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with its partner, Cytiva (formerly
Avacta Group PLC (AVCT.L) COVID-19 Rapid Antigen Test Manufacturing Partner
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva